Celebrating Galderma’s listing on the SIX Swiss Exchange
Galderma has officially entered an exciting, new chapter as a public company: we are now listed on the SIX Swiss Exchange as GALD.
As of Friday, March 22, 2024, Galderma is listed as a public company on the SIX Swiss Exchange. This milestone event marks a major turning point in our growth journey – one that is primed to propel us further toward our bold ambition to become the leading dermatology company in the world.
As a public company on Europe’s 3rd largest stock exchange, we are taking stock of our success and reflecting on what this achievement means for our purpose of advancing dermatology for every skin story.
Keeping a steady focus
Becoming a public company is a concrete testament to how far we’ve come over the course of our over 40-year heritage of leading in dermatology.
This milestone is the direct result of our commitment to excellence – a track record that continues to unfold in tangible outcomes: our initial public offering (IPO) has made history as the largest placement volume in Switzerland since 2017, foreshadowing unlimited possibilities for Galderma’s expansion in the future.
But this accomplishment is more than a reflection of decades of persistent research and development. It’s also a direct result of our unwavering focus on meeting the evolving needs of consumers and patients across the full spectrum of dermatology: Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Our purpose is the driving force behind everything we do and our establishment as an industry leader. As we continue to execute our growth strategy, we remain uniquely focused on this objective.
The future awaits
Galderma’s status as a publicly listed company represents a major turning point in our growth story. However, as we take this new step together, our focus remains firmly on what has taken us this far: a unique, Integrated Dermatology Strategy driving sustainable growth; operational excellence and premium execution; and disruptive innovation.
As we move forward, we will continue to let these pillars guide our work to meet individual consumer and patient needs with superior outcomes.
Access to the press announcement issued by the SIX Swiss Exchange here.